Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000254240 | SCV000312145 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000398344 | SCV000383302 | likely benign | Charlevoix-Saguenay spastic ataxia | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000456504 | SCV000562825 | benign | Spastic paraplegia | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000254240 | SCV001475441 | benign | not specified | 2019-11-12 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000398344 | SCV001750101 | benign | Charlevoix-Saguenay spastic ataxia | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000676350 | SCV001938935 | benign | not provided | 2018-09-13 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001848026 | SCV002104963 | benign | Hereditary spastic paraplegia | 2021-08-30 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000676350 | SCV005219339 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000676350 | SCV000802124 | benign | not provided | 2016-02-22 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000398344 | SCV001459475 | benign | Charlevoix-Saguenay spastic ataxia | 2020-09-16 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000676350 | SCV002036743 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000254240 | SCV002037872 | benign | not specified | no assertion criteria provided | clinical testing |